These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9205821)

  • 1. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
    Umemura K; Kondo K; Ikeda Y; Kobayashi T; Urata Y; Nakashima M
    Br J Clin Pharmacol; 1997 Jun; 43(6):613-8. PubMed ID: 9205821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
    Umemura K; Kondo K; Ikeda Y; Nishimoto M; Hiraga Y; Yoshida Y; Nakashima M
    J Clin Pharmacol; 1999 May; 39(5):462-70. PubMed ID: 10234593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
    Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
    J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
    Morain P; Robin JL; De Nanteuil G; Jochemsen R; Heidet V; Guez D
    Br J Clin Pharmacol; 2000 Oct; 50(4):350-9. PubMed ID: 11012558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
    Zhu Y; Statkevich P; Cutler DL
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers.
    Umemura K; Ikeda Y; Kondo K; Nakashima M; Naganuma H; Hisaoka M; Nishino H; Tajima M
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2664-9. PubMed ID: 9420036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
    van Marle S; van Vliet A; Sollie F; Kambayashi Y; Yamada-Sawada T
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):282-93. PubMed ID: 15968885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
    Ikeda Y; Umemura K; Kondo K; Nakashima M; Kobayashi T; Takahashi M
    Br J Clin Pharmacol; 2002 Nov; 54(5):453-62. PubMed ID: 12445023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.
    Swaisland H; Laight A; Stafford L; Jones H; Morris C; Dane A; Yates R
    Clin Pharmacokinet; 2001; 40(4):297-306. PubMed ID: 11368294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
    Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
    Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat.
    Jalkanen AJ; Hakkarainen JJ; Lehtonen M; Venäläinen T; Kääriäinen TM; Jarho E; Suhonen M; Forsberg MM
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):443-51. PubMed ID: 21707925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats.
    Toide K; Okamiya K; Iwamoto Y; Kato T
    J Neurochem; 1995 Jul; 65(1):234-40. PubMed ID: 7540663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
    Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
    Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer.
    Toide K; Iwamoto Y; Fujiwara T; Abe H
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1370-8. PubMed ID: 7562510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
    Wyld PJ; Grant J; Lippi A; Criscuoli M; Del Re G; Subissi A
    Br J Clin Pharmacol; 1994 Nov; 38(5):421-5. PubMed ID: 7893583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.